Newborn Screening in the Czech Republic and in Europe

1. Magnusson G, Persson U. Screening for congenital cataracts: a cost-consequence analysis of eye examination at maternity wards in comparison to well-baby clinics. Acta Paediatr. 2005;94(8): 1089–1095.

2. Magnusson G, Thiringer K. Screening for congenital cataract is best done at the obstetrical department. Complementary examination at the child health center is recommended. Lakartidningen. 2002;99(7): 620–625.

3. Fitzpatrick E, Durieux-Smith A, Eriks-Brophy A, et al. The impact of newborn hearing screening on communication development. J. Med. Screen. 2007;14(3): 123–131.

4. Scott JE, Lee RE, Hunter EW, et al. Ultrasound screening of newborn urinary tract. Lancet 1991;338(8782–8783): 1571–1573.

5. Zajištění celoplošného novorozeneckého laboratorního screeningu a následné péče. Věstník MZ ČR, VII, 2003;částka 7: 14–24.

6. Loeber JG. Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis. 2007;30(4):430–438.

7. Autti-Ramo I, Makela M, Sintonen H, et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatr. 2005;94(8): 1126–1136.

8. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338–343.

9. Guthrie R. Screening for phenylketonuria. Triangle 1969;9(3): 104–109.

10. Wilson JMC, Jungner G: Principles and Practice of Screening for Disease. Publ. Health Pap. 1968;WHO 34.

11. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results. Pediatrics 2006;118(2):448–456.

12. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J. Inherit. Metab. Dis. 2006;677–682. Epub 2006 Aug 17.

13. Gurian EA, Kinnamon DD, Henry JJ, et al. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006;117(6): 1915–1921.

14. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290(19): 2564–2572.

15. Giannetta T. Oh, no! The newborn screen is positive! J. Pediatr. Health Care 2007;21(1): 69–71.

16. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J. Inherit. Metab. Dis. 2006;29(5):677–682.

17. Blehová B, Pažoutová M, Bloudková D, et al. Zhodnocení screeningu fenylketonurie za šest let trvání laboratoře. Čes.-slov. Pediat. 1976;31(7): 399–400.

18. Čechák P, Hejcmanová L, Procházková D, et al. Výsledky screeningu hyperfenylalaninémií v českých zemích v letech 1970–2000. Čes.-slov. Pediat. 2001;56(11): 667–670.

19. Larsen PR, Merker A, Parlow AF. Immunoassay of human TSH using dried blood samples. J. Clin. Endocrinol. Metab. 1976;42(5): 987–990.

20. Irie M, Enomoto K, Enomoto H, et al. Microdetermination of TSH in dried blood spot — its use in the mass-screening for congenital or juvenile primary hypothyroidism. Nippon Naibunpi Gakkai Zasshi 1976;52(3): 243–247.

21. Larsen PR, Merker A, Parlow AF. Immunoassay of human TSH using dried blood samples. J. Clin. Endocrinol. Metab. 1976;42(5): 987–990.

22. Hníková O, Kračmar P, Zelenka Z, et al. Screening of congenital hypothyroidism in newborns in Bohemia and Moravia. Endocrinol. Exp. 1989;23(2): 117–123.

23. Pang S, Hotchkiss J, Drash AL, et al. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 1977;45(5): 1003–1008.

24. Torresani T, Biason-Lauber A. Congenital adrenal hyperplasia: diagnostic advances. J. Inherit. Metab. Dis. 2007;30(4): 563–575.

25. Votava F, Kračmar P, Rákosníková V, et al. Novorozenecký screening kongenitální adrenální hyperplazie v České republice – výsledky roční pilotní studie u chlapců. Čes.-slov. Pediat. 2002;57(12): 690–696.

26. Riepe FG, Sippell WG. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev. Endocr. Metab. Disord. 2007; Sept21: [Epub ahead of print].

27. Hoffmann G, Pollitt R, Torresani T, et al. Focus on neonatal screening. J. Inherit. Metab. Dis. 2007;30(4): 417.

28. Howell RR, Engelson G. Structures for clinical follow-up: newborn screening. J. Inherit. Metab. Dis. 2007;30(4): 600–605.

29. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J. Inherit. Metab. Dis. 2007;30(4): 439–444.

30. van der Hilst CS, Derks TG, Reijngoud DJ, et al. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands. J. Pediatr. 2007;151(2): 115–120.

31. Cipriano LE, Rupar CA, Zaric GS. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model. Value Health 2007;10(2): 83–97.

32. Webster D. Quality performance of newborn screening systems: strategies for improvement. J. Inherit. Metab. Dis. 2007;30(4): 576–584.

33. Elvers LH, Loeber JG, Dhondt JL, et al. First ISNS Reference Preparation for Neonatal Screening for thyrotropin, phenylalanine and 17alpha-hydroxyprogesterone in blood spots. J. Inherit. Metab. Dis. 2007;30(4): 609.

34. Olney RS, Moore CA, Ojodu JA, et al. Storage and use of residual dried blood spots from state newborn screening programs. J. Pediatr. 2006;148(5): 618–622.

35. Wilcken B. Newborn screening for cystic fibrosis: techniques and strategies. J. Inherit. Metab. Dis. 2007;30(4): 537–543.

36. Sims EJ, Clark A, McCormick J, et al. United Kingdom Cystic Fibrosis Database Steering Committee: Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics 2007;119(1): 19–28.

37. Sims EJ, Mugford M, Clark A, et al. Cystic Fibrosis Database Steering Committee: Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007;369(9568): 1187–1195.

38. Comeau AM, Accurso FJ, White TB, et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007;119(2): 495–518.

39. Holubová A, Balaščáková M, Skalická V, et al. Novorozenecký screening cystické fibrózy v České republice: závěry pilotní studie. Čes.-slov. Pediat. 2007;62(4): 187–195.

40. Millington DS, Kodo N, Norwood DL, et al. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J. Inherit. Metab. Dis. 1990;13(3): 321–324.

41. Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin. Chem. 1993;39(1): 66–71.

42. Rashed MS, Ozand PT, Bucknall MP, et al. Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr. Res. 1995;38(3): 324–331.

43. Turecek F, Scott CR, Gelb MH. Tandem mass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol. Biol. 2007;359: 143–157.

44. Chrastina P, Šťastná S, Myšková H, Zeman J. Tandemová hmotnostní spektrometrie – budoucnost novorozeneckého screeningu dědičných metabolických poruch. Čes.-slov. Pediat. 2003;7: 464–467.

45. Chrastina P, Košťálová E, Paulová H, et al. Experience with screening by tandem mass spectrometry in the Czech Republic. The 5th European ISNS Congresss in Newborn Screening, June 10–12th 2007, Reykjavík, Island, Abstracts Book, p. 41.

46. Dhondt JL. Neonatal screening: from the ‘Guthrie age’ to the ‘genetic age’. J. Inherit. Metab. Dis. 2007;30(4): 418–422.

47. Alexander D, van Dyck PC. A vision of the future of newborn screening. Pediatrics 2006;117(5): S350–S354.

48. Green NS, Pass KA. Neonatal screening by DNA microarray: spots and chips. Nat. Rev. Genet. 2005;6(2): 147–151.

49. Tachibana S, Suzuki M, Asano Y. Application of an enzyme chip to the microquantification of l-phenylalanine. Anal. Biochem. 2006;359(1): 72–78.